Asia On The Move: As China Slows, Returnees Reconsider Options
This article was originally published in PharmAsia News
Executive Summary
The China economic slowdown appears to be starting to affect life science returnee talent, with two executives leaving their R&D and investment executive positions at top multinationals in the past few months alone. Meanwhile, the China FDA is preparing to announce a plethora of new directors and personnel changes are taking place at regional firms including ASLAN, Kyowa Hakko Kirin and Terumo.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.